Here, we wanted to evaluate, whether CD137 stimulation by agonistic anti-CD137 antibodies holds the potential to bolster the monocytes’ tumoricidal activity, especially in view of a combination with tumor-targeting mAbs [9]. This evidence concerns the gene TNFRSF9 and neoplasm.